ANGELINI's REV-EYES APPROVED; LEDERLE/STORZ PREPARING FOR APRIL LAUNCH

Angelini Pharmaceuticals' Rev-Eyes eyedrop to reverse pupillary dilation caused by mydriatic agents commonly used during ophthalmic examinations was approved by FDA on Dec. 31. Rev-Eyes (dapiprazole) was given a "1-B" rating by FDA, designating a new molecular entity representing a modest therapeutic advantage. It is the first product approved for this indication, Angelini said, and the first alpha blocker approved for any ophthalmic use. The product is the first approval for the River Edge, N.J.- based company, which was established seven years ago. Angelini Pharmaceuticals is the U.S. subsidiary of the Rome-based Angelini Group, a privately owned company with interests in consumer and health-care products. Rev-Eyes was codeveloped by American Cyanamid's Lederle Labs/Storz Ophthalmic Division, which has marketing rights in the U.S. and Canada. Storz estimates that the product could potentially be used in up to half of the 60 mil. ophthalmic exams performed in the U.S. annually. Storz said that it is aiming for an April launch, and anticipates a late 1991 approval in Canada. Storz will detail the product with 100 sales reps in the U.S. Because Rev-Eyes will be used by physicians in their own offices rather than by prescription, Storz said, most sales are expected to be directly to physicians rather than to wholesalers. While the exact price has not yet been determined, Storz said it expects the list price to be approximately $ 20 for a multidose bottle with enough product for 15 patients. Dapiprazole will be manufactured in Aprilia, Italy by Angelini, although the product will be reformulated and packaged in the U.S. by Abbott under contract from Angelini. Angelini has not disclosed specific terms of its agreements with either Storz or Abbott.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Danish Medicines Agency Wants Companies To Use “Better Data Format” To Submit Bioequivalence Studies

 

The Danish Medicines Agency is requesting that data from bioequivalence studies to be submitted in the CDISC format in addition to the current eCTD format. It believes the move will make it easier for the agency claims to access and analyze data and will reduce the burden for applicants.

England’s NICE Hunts For New Chief As Sam Roberts Prepares To Step Down

 

Sam Roberts, chief executive of the health technology assessment institute, NICE, will step down from her role at the end of the year. The agency is now on the lookout for a new leader, who will be the fourth in its history.

NDA User Fees Will Grow 8.6% Next Year As FDA Projects More Applications But Fewer Sponsor Meetings

 

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.